Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by ...

So, I think more to come on how first line selection might evolve in the next few years depending on results from other ...

So, one of the areas of highest unmet needs in triple-negative breast cancer is the recurrence post-chemo and immunotherapy ...

The most common adverse events reported in the neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin arm were pruritus, alopecia, diarrhea, fatigue and anemia. No new safety signals were ...

Research and development expenses were $13.7 million for the three months ended September 30, 2025, compared to $20.2 million for the three months ended September 30, 2024. The company recognized $0.6 ...

Merck & Co. Inc. (NYSE:MRK) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 30, Merck & Co.

A new review was published in Volume 12 of Oncoscience on October 13, 2025, titled "Targeted therapies and resistance ...

Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data ...

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck ...

The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient ...

Anixa Biosciences to present a more complete phase 1 data readout at SABCS in December. Read my ANIX stock update and know ...